If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Quick Contact
    • Aptar Pharma
    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation
    Health, Pharmaceuticals, OTC (Over the Counter) Drugs, Primary Packaging, Bottles, Dispensing Closures, Bulbs, Pipettes, Droppers, Drug Delivery Devices, Laboratory, Testing, Certification

    Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH® RELIEVA™ PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S.

    This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products. Launched along with REFRESH® RELIEVA™ PF are REFRESH® RELIEVA™ and REFRESH® RELIEVA™ FOR CONTACTS. This new line of artificial tear formulations from Allergan is specifically developed to relieve discomfort due to eye dryness and to prevent further irritation. REFRESH®, a doctor recommended brand for artificial tears, further expands its portfolio by offering the only family of products in the U.S. with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and Allergan’s HydroCell™ technology. This formulation enables hydration and maintains the volume of cells on the ocular surface.

    Allergan is a leader in eye care, with 70 years of experience and over 125 eye care products launched, among those some of the most innovative products in the industry. Aptar Pharma has been partnering with Allergan across numerous preservative-free product launches.

    Chemical preservatives are often used in eye drops to ensure sterility of the drops in multidose bottles. When used in short-term treatments, they are mostly well-tolerated. For long-term use, such as in chronic conditions that include dry eye, preservative-free products are preferred. Preservatives have been known to cause signs and symptoms of irritation, allergy and ocular surface toxicity.

    “Our Ophthalmic Squeeze Dispenser technology has been launched with close to 250 preservative-free eye care products worldwide. Its proven unrivalled microbiological safety combined with a diverse technological platform enables our customers to introduce their formulations to market in the purest form and offering outstanding convenience, meeting the needs of consumers and patients,” explained Matthias Birkhoff, VP Business Development, Aptar Pharma.

    “By offering the first and only FDA-reviewed technology for multidose preservative-free systems, our customers can rely on Aptar Pharma’s comprehensive service package to support their development of eye care products without preservatives.”

    Photo: Courtesy of Allergan

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Brand Launch
    • English
    • Modified 27 Jan 2022
    • Hits 1660
    Manjushree India
    Webpackaging
    Condensa